TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21507257

Group type: EXPERIMENTAL
Intervention: Structured interview followed by visits every 2-3 weeks to the end of dose reduction
Number of subjects: 495

Group type: EXPERIMENTAL
Intervention: Structured interview plus delivery of written instructions to self-reduce benzodiazepine dose
Number of subjects: 495

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 495

Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 495
Study: 18713842

Group type: EXPERIMENTAL
Intervention: Metyrapone (METY, 3 g)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Ketoconazole (KTCZ, 1.2 g)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo (PLAC)
Number of subjects: 7
Study: 16828435

Group type: COMPARATOR
Intervention: Treadmill training (n = 13)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Cycle training (n = 15)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (n = 14)
Number of subjects: 42
Study: 12816022

Group type: EXPERIMENTAL
Intervention: Pharmaceutical care (including medical record review, medication history review, pharmacotherapeutic evaluation, patient medication education and monitoring over one year)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Pharmaceutical care
Number of subjects: 69

Group type: COMPARATOR
Intervention: Standard medical care
Number of subjects: 69
Study: 10234494

Group type: EXPERIMENTAL
Intervention: Dopamine 5 micrograms kg‐1 min‐1
Number of subjects: 9

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 9
Study: 9199125

Group type: EXPERIMENTAL
Intervention: Theophylline (3.5 mg/kg) administered intravenously to humans with mixed-form hyperlipidemia
Number of subjects: 2

Group type: COMPARATOR
Intervention: Theophylline (12 mg/kg) administered intravenously to hyperlipidemic rabbits
Number of subjects: 2
Study: 1842009

Group type: EXPERIMENTAL
Intervention: Alpinia speciosa
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Elephantopus scaber
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 6849784

Group type: EXPERIMENTAL
Intervention: Intravenous chloroquine (300 mg)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Oral solution chloroquine (300 mg)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Chloroquine tablets (300 mg)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Oral doses of chloroquine
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: High frequency audiometry
Number of subjects: 11
Study: 31514745

Group type: EXPERIMENTAL
Intervention: Repeat HIV self-testing (HIVST) under observation of a trained nurse counsellor
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Blood-based rapid HIV testing
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: DNA/PCR testing (considered gold-standard)
Number of subjects: 95
Study: 31068019

Group type: EXPERIMENTAL
Intervention: Kinesio taping (KT) applied 2 times per week for 3 weeks
Number of subjects: 66

Group type: COMPARATOR
Intervention: Pressure garment (PG) 20‐60 mmHg for at least 15‐18 hours per day for 3 weeks
Number of subjects: 66
Study: 27365077

Group type: EXPERIMENTAL
Intervention: Genta‐Coll group (G‐group)
Number of subjects: 996

Group type: EXPERIMENTAL
Intervention: InteguSeal group (I‐group)
Number of subjects: 996

Group type: COMPARATOR
Intervention: Standard group (S‐group)
Number of subjects: 996
Study: 25455421

Group type: EXPERIMENTAL
Intervention: Whey protein supplementation
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Soy protein supplementation
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Whey and Soy protein groups combined
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Whey and Soy protein groups
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 38
Study: 23292038

Group type: EXPERIMENTAL
Intervention: HA ester patching (Epifilm®)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Spontaneous closure
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: HA ester patching (Epifilm®) and Spontaneous closure
Number of subjects: 155
Study: 22586827

Group type: EXPERIMENTAL
Intervention: PostureJac (SomatoCentric Systems, Inc., Toronto, Ontario, Canada)
Number of subjects: 45

Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 45

Group type: COMPARATOR
Intervention: Treatment-control (table stabilization)
Number of subjects: 45
Study: 19556794

Group type: EXPERIMENTAL
Intervention: Billroth I reconstruction
Number of subjects: 31

Group type: COMPARATOR
Intervention: Roux-en-Y reconstruction
Number of subjects: 31
Study: 16683432

Group type: EXPERIMENTAL
Intervention: Autologous iliac crest graft (group A, n=20)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Autogenous bone and anterior cervical locking plates (group B, n=20)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Syncage‐C filled with local autograft reamings (group C, n=20)
Number of subjects: 60
Study: 15592329

Group type: EXPERIMENTAL
Intervention: Fluconazole (200 mg daily) with Dapsone (100 mg daily)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Rifabutin (300 mg daily) with Dapsone (100 mg daily)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Fluconazole plus Rifabutin with Dapsone (100 mg daily)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Clarithromycin (500 mg twice daily) with Dapsone (100 mg daily)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Dapsone (100 mg daily) alone
Number of subjects: 23
Study: 11359439

Group type: EXPERIMENTAL
Intervention: HAART (Highly Active Antiretroviral Therapy) for 12 months
Number of subjects: 20
Study: 9644873

Group type: EXPERIMENTAL
Intervention: 300 mg/day of ZAM
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 7937908

Group type: EXPERIMENTAL
Intervention: Microsatellite alterations in tumors
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Microsatellite alterations detection in urine, sputum, and surgical margins
Number of subjects: 100
Study: 3218660

Group type: EXPERIMENTAL
Intervention: 1 alpha(OH)D3 treatment (2 micrograms for 3 months)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 48
Study: 30100304

Group type: EXPERIMENTAL
Intervention: Kinesio taping (KT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham taping (ST)
Number of subjects: 40
Study: 27785091

Group type: EXPERIMENTAL
Intervention: Botulinum toxin‐A (BTX‐A) injection
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS)
Number of subjects: 29
Study: 25344113

Group type: EXPERIMENTAL
Intervention: Argatroban
Number of subjects: 66

Group type: COMPARATOR
Intervention: Lepirudin
Number of subjects: 66
Study: 23562583

Group type: EXPERIMENTAL
Intervention: Happy Being Me intervention
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 88
Study: 21346512

Group type: EXPERIMENTAL
Intervention: Once-daily DRV/r 800/100 mg
Number of subjects: 590

Group type: COMPARATOR
Intervention: Twice-daily DRV/r 600/100 mg
Number of subjects: 590
Study: 19054926

Group type: EXPERIMENTAL
Intervention: Montelukast and loratadine
Number of subjects: 115

Group type: COMPARATOR
Intervention: Placebo and loratadine
Number of subjects: 115
Study: 17012486

Group type: EXPERIMENTAL
Intervention: Screening laboratory tests for immunodeficiency
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Consultation with a specialist
Number of subjects: 0
Study: 14517728

Group type: EXPERIMENTAL
Intervention: Basilic vein transposition in upper arm (brachiobasilic fistula)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Basilic vein transposition in forearm (radiobasilic fistula)
Number of subjects: 20
Study: 10894321

Group type: EXPERIMENTAL
Intervention: Enalapril 5-20 mg od
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Nifedipine 30-90 mg od
Number of subjects: 39

Group type: COMPARATOR
Intervention: Comparison of enalapril and nifedipine
Number of subjects: 39
Study: 8815972

Group type: EXPERIMENTAL
Intervention: Intercostal cryoanalgesia
Number of subjects: 100

Group type: COMPARATOR
Intervention: Pharmacological analgesia ad libitum (Control)
Number of subjects: 100
Study: 1422722

Group type: EXPERIMENTAL
Intervention: Shouldice repair
Number of subjects: 322

Group type: COMPARATOR
Intervention: plication darn
Number of subjects: 322
Study: 7402771

Group type: EXPERIMENTAL
Intervention: Oral salbutamol (0.15 mg/kg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Salbutamol aerosol (0.2 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Oral salbutamol
Number of subjects: 16

Group type: COMPARATOR
Intervention: Salbutamol aerosol
Number of subjects: 16
Study: 31818868

Group type: EXPERIMENTAL
Intervention: Electronic medical record triggers, provider education, and peer comparison
Number of subjects: 0
Study: 30481106

Group type: EXPERIMENTAL
Intervention: Commercial scale (CS) vaccine lot 1
Number of subjects: 1197

Group type: EXPERIMENTAL
Intervention: Commercial scale (CS) vaccine lot 2
Number of subjects: 1197

Group type: EXPERIMENTAL
Intervention: Commercial scale (CS) vaccine lot 3
Number of subjects: 1197

Group type: COMPARATOR
Intervention: Pooled Commercial scale (CS) group
Number of subjects: 1197

Group type: COMPARATOR
Intervention: Licensed pilot scale (LPS) vaccine
Number of subjects: 1197

Group type: COMPARATOR
Intervention: All groups (CS and LPS)
Number of subjects: 1197
Study: 28164777

Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 26017930

Group type: EXPERIMENTAL
Intervention: Child recall questionnaire
Number of subjects: 50

Group type: COMPARATOR
Intervention: Parent recall questionnaire
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Child diary
Number of subjects: 50
Study: 22827502

Group type: COMPARATOR
Intervention: Abstinent individuals at 6 months
Number of subjects: 995

Group type: COMPARATOR
Intervention: Low-risk drinkers at 6 months
Number of subjects: 995

Group type: COMPARATOR
Intervention: Drinking groups (abstinent, low-risk, heavy)
Number of subjects: 995
Study: 21127478

Group type: EXPERIMENTAL
Intervention: Family functioning score ≥2
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Family functioning score
Number of subjects: 408
Study: 19445861

Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.5 mg/kg)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 65
Study: 17226809

Group type: EXPERIMENTAL
Intervention: Retropubic prostatectomy
Number of subjects: 200

Group type: COMPARATOR
Intervention: Perineal prostatectomy
Number of subjects: 200
Study: 16648084

Group type: EXPERIMENTAL
Intervention: Cranial osteopathic manipulation
Number of subjects: 28

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 28
Study: 14665593

Group type: EXPERIMENTAL
Intervention: Personalised feedback on fitness and health status
Number of subjects: 299

Group type: COMPARATOR
Intervention: Reference group (no feedback)
Number of subjects: 299
Study: 9918518

Group type: EXPERIMENTAL
Intervention: D allele of the ACE gene
Number of subjects: 348

Group type: COMPARATOR
Intervention: Control group (no stroke)
Number of subjects: 348
Study: 8703690

Group type: EXPERIMENTAL
Intervention: Radiation therapy (20 Gy in five fractions)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Resection of the brain metastasis followed by postoperative radiation
Number of subjects: 0
Study: 2127786

Group type: EXPERIMENTAL
Intervention: Interferon (2 million units, subcutaneous injections three times weekly for 6 months)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo (subcutaneous injections three times weekly for 6 months)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Interferon (2 million units)
Number of subjects: 41
Study: 7381999

Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide (3 percent) instillation into the urethral catheter drainage bag
Number of subjects: 31

Group type: COMPARATOR
Intervention: Conventional drainage
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide (3 percent) instillation
Number of subjects: 31
Study: 29543135

Group type: EXPERIMENTAL
Intervention: Cocoa flavanols (CF)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 28302422

Group type: EXPERIMENTAL
Intervention: Paramedic protocol with community care referral
Number of subjects: 5914

Group type: COMPARATOR
Intervention: Control care as usual
Number of subjects: 5914
Study: 26161000

Group type: EXPERIMENTAL
Intervention: Group V (vehicle onboard cognitive training program)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Group P (personal computer cognitive training program)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Group C (crossword puzzle training)
Number of subjects: 37
Study: 24660271

Group type: EXPERIMENTAL
Intervention: Essential oil-containing mouthrinse (EO)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: 0.075% cetylpyridinium chloride mouthrinse (CPC)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Negative control (5% hydroalcohol rinse)
Number of subjects: 185
Study: 21205944

Group type: EXPERIMENTAL
Intervention: ACEF(low)
Number of subjects: 1707

Group type: EXPERIMENTAL
Intervention: ACEF(mid)
Number of subjects: 1707

Group type: EXPERIMENTAL
Intervention: ACEF(high)
Number of subjects: 1707
Study: 18507536

Group type: EXPERIMENTAL
Intervention: Complete ostial pulmonary vein isolation attempted regardless of anatomical relationship to the esophagus (group A)
Number of subjects: 43
Study: 16620257

Group type: EXPERIMENTAL
Intervention: CenteringPregnancy group prenatal care
Number of subjects: 0
Study: 12821430

Group type: EXPERIMENTAL
Intervention: OPCAB
Number of subjects: 4953

Group type: COMPARATOR
Intervention: CCAB
Number of subjects: 4953
Study: 10682943

Group type: EXPERIMENTAL
Intervention: Symptom-limited exercise testing for total work capacity (TWC, kg.m)
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Symptom-limited exercise testing for peak oxygen consumption (VO2peak, mL/kg/min)
Number of subjects: 265
Study: 8656171

Group type: EXPERIMENTAL
Intervention: Erythromycin 250 mg four times daily for 10 days
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 1672176

Group type: EXPERIMENTAL
Intervention: ICI 204.219 (40 mg single oral dose)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 10
Study: 6307464

Group type: EXPERIMENTAL
Intervention: Intravenous acyclovir 5 mg/kg twice daily during granulocytopenia
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Intravenous acyclovir
Number of subjects: 59
Study: 31977370

Group type: EXPERIMENTAL
Intervention: 250 mg chlorzoxazone 3 times daily for the first 7 days postoperatively
Number of subjects: 393

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 393
Study: 31383725

Group type: EXPERIMENTAL
Intervention: Spin identified in abstracts of RCTs
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Spin in titles
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Spin in abstract results sections
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Spin in abstract conclusion sections
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Simultaneous spin in results and conclusions sections
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Industry funding and spin relationship
Number of subjects: 116
Study: 28552271

Group type: COMPARATOR
Intervention: Standard Valsalva maneuver (VM)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Modified Valsalva maneuver (VM)
Number of subjects: 56
Study: 26434934

Group type: EXPERIMENTAL
Intervention: AMG 151 (50, 100, or 200mg twice daily)
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: AMG 151 (100, 200, or 400mg once daily)
Number of subjects: 236

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 236
Study: 24225595

Group type: EXPERIMENTAL
Intervention: Low-dose whey protein isolate (0.8 g·kg1·d1; W1)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: High-dose whey protein isolate (1.6 g·kg1·d1; W2)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control condition (typical mixed diet with 10% protein)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo condition (calorically matched with carbohydrate)
Number of subjects: 9
Study: 22423128

Group type: EXPERIMENTAL
Intervention: Linezolid (exact dosage and duration not specified)
Number of subjects: 1
Study: 19369380

Group type: EXPERIMENTAL
Intervention: Extensively hydrolyzed casein (eHF-C)
Number of subjects: 1840

Group type: COMPARATOR
Intervention: Partially hydrolyzed whey (pHF-W)
Number of subjects: 1840

Group type: COMPARATOR
Intervention: Extensively hydrolyzed whey (eHF-W)
Number of subjects: 1840

Group type: COMPARATOR
Intervention: Cow-milk formula (CMF)
Number of subjects: 1840

Group type: COMPARATOR
Intervention: Breastfeeding
Number of subjects: 1840
Study: 17186304

Group type: EXPERIMENTAL
Intervention: Exercise Group (EG) - 20 subjects
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control Group (CG) - 10 subjects
Number of subjects: 30
Study: 15058116

Group type: EXPERIMENTAL
Intervention: Sufentanil 25 micrograms
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Tramadol 100 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Clonidine 1 microgram.kg‐1
Number of subjects: 60

Group type: COMPARATOR
Intervention: Lignocaine with 5 ml saline (Control Group L)
Number of subjects: 60
Study: 11407430

Group type: EXPERIMENTAL
Intervention: Indirectly related words (e.g., sofa) used as primes for low-frequency inconsistent words in naming tasks.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Indirectly related words (e.g., sofa) used as primes for high-frequency inconsistent words in a speeded naming task.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Consistent words used as targets in naming tasks.
Number of subjects: 0
Study: 9404209

Group type: EXPERIMENTAL
Intervention: Acuson 128
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Siemens Quantum
Number of subjects: 63

Group type: COMPARATOR
Intervention: Acuson 128 and Siemens Quantum
Number of subjects: 63

Group type: COMPARATOR
Intervention: In vitro comparisons
Number of subjects: 63
Study: 8219679

Group type: EXPERIMENTAL
Intervention: Xue Zhi Ling
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group (panagin)
Number of subjects: 92
Study: 3306500

Group type: EXPERIMENTAL
Intervention: Intravenously administered cefuroxime and metronidazole (three-dose perioperative course)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Suction drainage of the vaginal vault
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 0
Study: 29371115

Group type: EXPERIMENTAL
Intervention: TTM at 33 °C
Number of subjects: 939

Group type: COMPARATOR
Intervention: TTM at 36 °C
Number of subjects: 939

Group type: EXPERIMENTAL
Intervention: Sedation administered in treatment groups
Number of subjects: 939
Study: 27180890

Group type: EXPERIMENTAL
Intervention: Macitentan 10 mg once daily
Number of subjects: 30
Study: 23931131

Group type: EXPERIMENTAL
Intervention: Papaya test meal
Number of subjects: 16

Group type: COMPARATOR
Intervention: Carrot test meal
Number of subjects: 16

Group type: COMPARATOR
Intervention: Tomato test meal
Number of subjects: 16
Study: 23394782

Group type: EXPERIMENTAL
Intervention: Controlled ovarian stimulation with highly purified human menopausal gonadotropin (hphMG) or recombinant FSH in a GnRH antagonist cycle.
Number of subjects: 749
Study: 20145572

Group type: EXPERIMENTAL
Intervention: Pilates exercise (12 weeks, 1 hour, 2 times per week)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no Pilates exercise)
Number of subjects: 50
Study: 18001794

Group type: EXPERIMENTAL
Intervention: Silicone catheter
Number of subjects: 85

Group type: COMPARATOR
Intervention: Hydrogel coated latex catheter
Number of subjects: 85
Study: 16432672

Group type: EXPERIMENTAL
Intervention: SpO(2)-sensitive adaptive backup support
Number of subjects: 11

Group type: COMPARATOR
Intervention: Conventional mechanical ventilation (control)
Number of subjects: 11
Study: 12638172

Group type: EXPERIMENTAL
Intervention: Smoking habit
Number of subjects: 9629
Study: 10761538

Group type: EXPERIMENTAL
Intervention: Standardized ginseng extract
Number of subjects: 384

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 384
Study: 7628032

Group type: EXPERIMENTAL
Intervention: Oral clonidine (5 micrograms.kg-1)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control (no clonidine)
Number of subjects: 38
Study: 1974498

Group type: EXPERIMENTAL
Intervention: S(−)‐CARV after i.v. administration
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: R(+)‐CARV after i.v. administration
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: S(−)‐CARV after p.o. administration
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: R(+)‐CARV after p.o. administration
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both enantiomers
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: S(−)‐CARV and R(+)‐CARV
Number of subjects: 10
Study: 7220763

Group type: EXPERIMENTAL
Intervention: Evoked potentials (EPs) associated with hits
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Evoked potentials (EPs) associated with false affirmatives
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Evoked potentials (EPs) associated with misses and correct rejections
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Peak latencies
Number of subjects: 0
Study: 31174586

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) followed by rituximab
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo infusions of 1% albumin followed by 0.9% sodium chloride
Number of subjects: 80
Study: 29097298

Group type: EXPERIMENTAL
Intervention: Garmin Vivofit2®; behavioural feedback and goal setting session; and, five telephone‐delivered health coaching sessions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Garmin Vivofit2® only
Number of subjects: 0
Study: 27085996

Group type: EXPERIMENTAL
Intervention: EPA + DHA supplementation (600 mg EPA and 260 mg DHA per day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 24
Study: 24775812

Group type: COMPARATOR
Intervention: Ciprofloxacin (10 doses of 500 mg every 12 hours during 5 days)
Number of subjects: 671

Group type: EXPERIMENTAL
Intervention: Fosfomycin-trometamol (2 doses of 3g every 48 hours)
Number of subjects: 671
Study: 22683945

Group type: EXPERIMENTAL
Intervention: Trauma
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral Match
Number of subjects: 0